Biostax Corp.
Biostax Corp. operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. Its lead investigational drug candidate Lodonal, an once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Its programs also include Global Telehealth platform; Medtech asset,… Read more
Market Cap & Net Worth: Biostax Corp. (BTAX)
Biostax Corp. (PINK:BTAX) has a market capitalization of $15.74K ($15.74K) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #45247 globally and #14249 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biostax Corp.'s stock price $0.00 by its total outstanding shares 78713631 (78.71 Million).
Biostax Corp. Market Cap History: 2015 to 2025
Biostax Corp.'s market capitalization history from 2015 to 2025. Data shows change from $17.31 Billion to $15.74K (-75.57% CAGR).
Biostax Corp. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biostax Corp.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BTAX by Market Capitalization
Companies near Biostax Corp. in the global market cap rankings as of March 19, 2026.
Key companies related to Biostax Corp. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Biostax Corp. Historical Marketcap From 2015 to 2025
Between 2015 and today, Biostax Corp.'s market cap moved from $17.31 Billion to $ 15.74K, with a yearly change of -75.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $15.74K | -99.27% |
| 2024 | $2.16 Million | -62.33% |
| 2023 | $5.75 Million | -87.83% |
| 2022 | $47.23 Million | -79.93% |
| 2021 | $235.35 Million | -79.39% |
| 2020 | $1.14 Billion | +123.23% |
| 2019 | $511.64 Million | +44.44% |
| 2018 | $354.21 Million | -78.37% |
| 2017 | $1.64 Billion | -58.40% |
| 2016 | $3.94 Billion | -77.26% |
| 2015 | $17.31 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Biostax Corp. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.74K USD |
| MoneyControl | $15.74K USD |
| MarketWatch | $15.74K USD |
| marketcap.company | $15.74K USD |
| Reuters | $15.74K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.